GPN Vaccines is a biotechnology company developing a Streptococcus pneumoniae vaccine. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections) and each year it causes up to 2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined.

There are 100 known serotypes of S. pneumoniae and the most effective vaccine currently available, Pfizer’s Prevnar-20®, is designed to protect against twenty of those serotypes. Our approach to solving this problem is a whole-cell vaccine which is inactivated with a sterilising dose of high energy photons, preserving antigenic structures and enabling broad-spectrum immunity to be elicited to proteins present in all serotypes.